Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | POLB | P06746 | 3/20 | 0.72 |
| ▸ | GLS | O94925 | 6/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282603 | 0.92 | POLB (0.80) | ALDH1A1POLBGLSL3MBTL1GAA | |
| SCHEMBL28349039 | 0.89 | ALDH1A1 (0.58) | ALDH1A1POLBGLSL3MBTL1GAA | |
| SCHEMBL11866633 | 0.86 | — | — | |
| SCHEMBL14975757 | 0.86 | ALDH1A1 (0.95) | ALDH1A1POLBGLSL3MBTL1GAA | |
| SCHEMBL14977428 | 0.86 | ALDH1A1 (0.86) | ALDH1A1POLBGLSL3MBTL1GAA | |
| SCHEMBL14986945 | 0.84 | ALDH1A1 (1.00) | ALDH1A1POLBGLSL3MBTL1GAA | |
| SCHEMBL1968819 | 0.80 | ALDH1A1 (0.88) | ALDH1A1POLBGLSL3MBTL1GAA | |
| Hydrochloric Acid SCHEMBL20475888 | 0.78 | ALDH1A1 (0.85) | ALDH1A1POLBGLSL3MBTL1GAA | |
| SCHEMBL7323305 | 0.78 | ALDH1A1 (0.72) | ALDH1A1POLBGLSL3MBTL1GAA | |
| SCHEMBL17402474 | 0.78 | ALDH1A1 (0.79) | ALDH1A1POLBGLSL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | disclosed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | disclosed |
| CN-117024352-A | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-110719910-B | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | disclosed |
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
| US-20200377493-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2020-12-03 | — | — | US | disclosed |
| EP-3601269-A1 | NOVEL INHIBITORS | Probiodrug AG (DE) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018178384-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | ALDH1A1 1183/4885POLB 1502/4885GLS 1/4885 |
| US-20200377493-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | ALDH1A1 1681/4885POLB 1286/4885GLS 2/4885 |
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | ALDH1A1 1490/4885POLB 1251/4885GLS 3/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | ALDH1A1 1415/4885POLB 927/4885GLS 1/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | ALDH1A1 1184/4885POLB 1457/4885GLS 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.